Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021994 | 0.85 | KMT2A (0.52) | KMT2AMMP2MMP9L3MBTL1CA2 | |
| SCHEMBL27717200 | 0.85 | KMT2A (0.52) | KMT2AMMP2MMP9L3MBTL1CA2 | |
| SCHEMBL5495801 | 0.85 | KMT2A (0.52) | KMT2AMMP2MMP9L3MBTL1CA2 | |
| SCHEMBL2248452 | 0.82 | ADAMTS4 (0.52) | KMT2AMMP2MMP9ADAMTS4ADAMTS5 | |
| SCHEMBL2247130 | 0.80 | KMT2A (0.48) | KMT2AMMP2MMP9L3MBTL1ADAMTS5 | |
| SCHEMBL29033836 | 0.79 | KMT2A (0.53) | KMT2AMMP2MMP9L3MBTL1ADAMTS4 | |
| SCHEMBL27138798 | 0.78 | CYP2C19 (0.44) | KMT2AMMP2ADAMTS4ADAMTS5MAPT | |
| SCHEMBL10889787 | 0.78 | NPSR1 (0.42) | MAPTKIF11NPSR1 | |
| SCHEMBL20299077 | 0.77 | KMT2A (0.45) | KMT2AMMP2MMP9L3MBTL1CA2 | |
| SCHEMBL2247878 | 0.77 | KMT2A (0.45) | KMT2AMMP2MMP9L3MBTL1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885MMP2 49/4885MMP9 27/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885MMP2 49/4885MMP9 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.